Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.

Judson I, Morden JP, Kilburn L, Leahy M, Benson C, Bhadri V, Campbell-Hewson Q, Cubedo R, Dangoor A, Fox L, Hennig I, Jarman K, Joubert W, Kernaghan S, López Pousa A, McNeil C, Seddon B, Snowdon C, Tattersall M, Toms C, Martinez Trufero J, Bliss JM.

Lancet Oncol. 2019 Jul;20(7):1023-1034. doi: 10.1016/S1470-2045(19)30215-3. Epub 2019 May 31.

2.

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.

Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M.

Lancet Oncol. 2019 Jul;20(7):1011-1022. doi: 10.1016/S1470-2045(19)30277-3. Epub 2019 May 28.

PMID:
31151904
3.

A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium.

Mueller S, Jain P, Liang WS, Kilburn L, Kline C, Gupta N, Panditharatna E, Magge SN, Zhang B, Zhu Y, Crawford JR, Banerjee A, Nazemi K, Packer RJ, Petritsch CK, Truffaux N, Roos A, Nasser S, Phillips JJ, Solomon D, Molinaro A, Waanders AJ, Byron SA, Berens ME, Kuhn J, Nazarian J, Prados M, Resnick AC.

Int J Cancer. 2019 Oct 1;145(7):1889-1901. doi: 10.1002/ijc.32258. Epub 2019 Apr 3.

PMID:
30861105
4.

Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy.

Panditharatna E, Kilburn LB, Aboian MS, Kambhampati M, Gordish-Dressman H, Magge SN, Gupta N, Myseros JS, Hwang EI, Kline C, Crawford JR, Warren KE, Cha S, Liang WS, Berens ME, Packer RJ, Resnick AC, Prados M, Mueller S, Nazarian J.

Clin Cancer Res. 2018 Dec 1;24(23):5850-5859. doi: 10.1158/1078-0432.CCR-18-1345. Epub 2018 Oct 15.

5.

A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system.

Manley PE, Trippett T, Smith AA, Macy ME, Leary SES, Boklan J, Cohen KJ, Goldman S, Kilburn LB, Dhall G, Devin J, Herzog CE, Partap S, Fauchet F, Badreddine E, Bernard JP, Chi SN.

Pediatr Blood Cancer. 2018 Sep;65(9):e27217. doi: 10.1002/pbc.27217. Epub 2018 May 11.

PMID:
29750396
6.

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM.

Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30.

8.

The Application and Feasibility of Using Routine Data Sources for Long-term Cancer Clinical Trial Follow-up.

Bhattacharya IS, Morden JP, Griffin C, Snowdon C, Brannan R, Bliss JM, Kilburn L.

Clin Oncol (R Coll Radiol). 2017 Dec;29(12):796-798. doi: 10.1016/j.clon.2017.10.007. Epub 2017 Oct 26. No abstract available.

9.

A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas.

Kilburn LB, Kocak M, Baxter P, Poussaint TY, Paulino AC, McIntyre C, Lemenuel-Diot A, Lopez-Diaz C, Kun L, Chintagumpala M, Su JM, Broniscer A, Baker JN, Hwang EI, Fouladi M, Boyett JM, Blaney SM.

Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26832. Epub 2017 Nov 1.

10.

Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.

Fribbens C, Garcia Murillas I, Beaney M, Hrebien S, O'Leary B, Kilburn L, Howarth K, Epstein M, Green E, Rosenfeld N, Ring A, Johnston S, Turner N.

Ann Oncol. 2018 Jan 1;29(1):145-153. doi: 10.1093/annonc/mdx483.

11.

TPOAb and Thyroid Function Are Not Associated with Breast Cancer Outcome: Evidence from a Large-Scale Study Using Data from the Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001).

Muller I, Kilburn LS, Taylor PN, Barrett-Lee PJ, Bliss JM, Ellis P, Ludgate ME, Dayan CM.

Eur Thyroid J. 2017 Jul;6(4):197-207. doi: 10.1159/000460246. Epub 2017 Apr 4.

12.

Long-Term Follow-Up of the Intergroup Exemestane Study.

Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM, Coombes RC.

J Clin Oncol. 2017 Aug 1;35(22):2507-2514. doi: 10.1200/JCO.2016.70.5640. Epub 2017 May 3.

13.

Treatment of the axilla in patients with primary breast cancer and low burden axillary disease: Limitations of the evidence from randomised controlled trials.

Robertson JF, Herrod PJ, Matthew J, Kilburn LS, Coles CE, Bradbury I.

Crit Rev Oncol Hematol. 2017 Feb;110:74-80. doi: 10.1016/j.critrevonc.2016.11.011. Epub 2016 Nov 25. Review.

PMID:
28109407
14.

Pediatric low-grade gliomas: implications of the biologic era.

Packer RJ, Pfister S, Bouffet E, Avery R, Bandopadhayay P, Bornhorst M, Bowers DC, Ellison D, Fangusaro J, Foreman N, Fouladi M, Gajjar A, Haas-Kogan D, Hawkins C, Ho CY, Hwang E, Jabado N, Kilburn LB, Lassaletta A, Ligon KL, Massimino M, Meeteren SV, Mueller S, Nicolaides T, Perilongo G, Tabori U, Vezina G, Warren K, Witt O, Zhu Y, Jones DT, Kieran M.

Neuro Oncol. 2017 Jun 1;19(6):750-761. doi: 10.1093/neuonc/now209. Review.

15.

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, Cristofanilli M, Andre F, Loi S, Loibl S, Jiang J, Bartlett CH, Koehler M, Dowsett M, Bliss JM, Johnston SR, Turner NC.

J Clin Oncol. 2016 Sep 1;34(25):2961-8. doi: 10.1200/JCO.2016.67.3061. Epub 2016 Jun 6.

PMID:
27269946
16.

Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer.

Coombes RC, Kilburn LS, Tubiana-Mathieu N, Olmos T, Van Bochove A, Perez-Lopez FR, Palmieri C, Stebbing J, Bliss JM.

Eur J Cancer. 2016 Jun;60:146-53. doi: 10.1016/j.ejca.2016.03.001. Epub 2016 Apr 26.

PMID:
27125966
17.

Separation of outer retinal layers secondary to selumetinib.

Avery RA, Trimboli-Heidler C, Kilburn LB.

J AAPOS. 2016 Jun;20(3):268-71. doi: 10.1016/j.jaapos.2016.01.012. Epub 2016 Apr 21.

18.

Clinicopathology of diffuse intrinsic pontine glioma and its redefined genomic and epigenomic landscape.

Panditharatna E, Yaeger K, Kilburn LB, Packer RJ, Nazarian J.

Cancer Genet. 2015 Jul-Aug;208(7-8):367-73. doi: 10.1016/j.cancergen.2015.04.008. Epub 2015 May 1. Review.

PMID:
26206682
19.

Enhancing collaborative leadership in palliative social work in oncology.

Jones B, Phillips F, Head BA, Hedlund S, Kalisiak A, Zebrack B, Kilburn L, Otis-Green S.

J Soc Work End Life Palliat Care. 2014;10(4):309-21. doi: 10.1080/15524256.2014.975319.

PMID:
25494928
20.

A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.

Kilburn LB, Kocak M, Decker RL, Wetmore C, Chintagumpala M, Su J, Goldman S, Banerjee A, Gilbertson R, Fouladi M, Kun L, Boyett JM, Blaney SM.

Neuro Oncol. 2015 Feb;17(2):303-11. doi: 10.1093/neuonc/nou114. Epub 2014 Nov 27.

21.

NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer.

Palmieri C, Cleator S, Kilburn LS, Kim SB, Ahn SH, Beresford M, Gong G, Mansi J, Mallon E, Reed S, Mousa K, Fallowfield L, Cheang M, Morden J, Page K, Guttery DS, Rghebi B, Primrose L, Shaw JA, Thompson AM, Bliss JM, Coombes RC.

Breast Cancer Res Treat. 2014 Dec;148(3):581-90. doi: 10.1007/s10549-014-3183-4. Epub 2014 Nov 14.

PMID:
25395314
22.

The challenges of long-term follow-up data collection in non-commercial, academically-led breast cancer clinical trials: the UK perspective.

Kilburn LS, Banerji J, Bliss JM; NCRI Breast Clinical Studies Group.

Trials. 2014 Sep 27;15:379. doi: 10.1186/1745-6215-15-379.

23.

ExCEL in Social Work: Excellence in Cancer Education & Leadership: An Oncology Social Work Response to the 2008 Institute of Medicine Report.

Otis-Green S, Jones B, Zebrack B, Kilburn L, Altilio TA, Ferrell B.

J Cancer Educ. 2015 Sep;30(3):503-13. doi: 10.1007/s13187-014-0717-8.

24.

A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report.

Su JM, Thompson P, Adesina A, Li XN, Kilburn L, Onar-Thomas A, Kocak M, Chyla B, McKeegan E, Warren KE, Goldman S, Pollack IF, Fouladi M, Chen A, Giranda V, Boyett J, Kun L, Blaney SM.

Neuro Oncol. 2014 Dec;16(12):1661-8. doi: 10.1093/neuonc/nou103. Epub 2014 Jun 7.

25.

Handheld optical coherence tomography during sedation in young children with optic pathway gliomas.

Avery RA, Hwang EI, Ishikawa H, Acosta MT, Hutcheson KA, Santos D, Zand DJ, Kilburn LB, Rosenbaum KN, Rood BR, Schuman JS, Packer RJ.

JAMA Ophthalmol. 2014 Mar;132(3):265-71. doi: 10.1001/jamaophthalmol.2013.7649.

26.

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.

Johnston SR, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, Im YH, Braybrooke JP, Brunt AM, Cheung KL, Jyothirmayi R, Robinson A, Wardley AM, Wheatley D, Howell A, Coombes G, Sergenson N, Sin HJ, Folkerd E, Dowsett M, Bliss JM; SoFEA investigators.

Lancet Oncol. 2013 Sep;14(10):989-98. doi: 10.1016/S1470-2045(13)70322-X. Epub 2013 Jul 29.

27.

Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.

Kilburn LB, Kocak M, Schaedeli Stark F, Meneses-Lorente G, Brownstein C, Hussain S, Chintagumpala M, Thompson PA, Gururangan S, Banerjee A, Paulino AC, Kun L, Boyett JM, Blaney SM.

Neuro Oncol. 2013 Jun;15(6):759-66. doi: 10.1093/neuonc/nos315. Epub 2013 Apr 16.

28.

Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.

Hwang EI, Jakacki RI, Fisher MJ, Kilburn LB, Horn M, Vezina G, Rood BR, Packer RJ.

Pediatr Blood Cancer. 2013 May;60(5):776-82. doi: 10.1002/pbc.24297. Epub 2012 Sep 13.

PMID:
22976922
29.

Insights into pediatric diffuse intrinsic pontine glioma through proteomic analysis of cerebrospinal fluid.

Saratsis AM, Yadavilli S, Magge S, Rood BR, Perez J, Hill DA, Hwang E, Kilburn L, Packer RJ, Nazarian J.

Neuro Oncol. 2012 May;14(5):547-60. doi: 10.1093/neuonc/nos067. Epub 2012 Apr 5.

30.

Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation.

Fallowfield LJ, Kilburn LS, Langridge C, Snowdon CF, Bliss JM, Coombes RC; IES Trial Steering Committee.

Br J Cancer. 2012 Mar 13;106(6):1062-7. doi: 10.1038/bjc.2012.43. Epub 2012 Feb 21.

31.

Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study.

Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens R, van de Velde CJ, Lønning PE, Morden J, Reise J, Cisar L, Menschik T, Coombes RC.

J Clin Oncol. 2012 Mar 1;30(7):709-17. doi: 10.1200/JCO.2010.33.7899. Epub 2011 Oct 31.

PMID:
22042946
32.

Adjuvant chemotherapy in older women (ACTION) study - what did we learn from the pilot phase?

Leonard R, Ballinger R, Cameron D, Ellis P, Fallowfield L, Gosney M, Johnson L, Kilburn LS, Makris A, Mansi J, Reed M, Ring A, Robinson A, Simmonds P, Thomas G, Bliss JM.

Br J Cancer. 2011 Oct 25;105(9):1260-6. doi: 10.1038/bjc.2011.377. Epub 2011 Oct 11.

33.

Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.

Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, Marty M, Coleman RE, Tubiana-Mathieu N, den Boer MO, Wardley A, Kilburn LS, Cooper D, Thomas MW, Reise JA, Wilkinson K, Hupperets P.

J Clin Oncol. 2011 Aug 20;29(24):3247-54. doi: 10.1200/JCO.2010.32.7254. Epub 2011 Jul 18.

PMID:
21768453
34.

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.

Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, Snee M, O'Brien M, Thomas G, Senan S, O'Byrne K, Kilburn LS, Spicer J, Landau D, Edwards J, Coombes G, Darlison L, Peto J; MARS trialists.

Lancet Oncol. 2011 Aug;12(8):763-72. doi: 10.1016/S1470-2045(11)70149-8. Epub 2011 Jun 30.

35.

Time to TEAM: exemestane, or tamoxifen then exemestane?

Coombes RC, Kilburn LS.

Lancet. 2011 Jan 22;377(9762):280-1. doi: 10.1016/S0140-6736(11)60073-1. No abstract available.

PMID:
21256370
36.

Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study.

Coleman RE, Banks LM, Girgis SI, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Bliss JM, Coombes RC, Kilburn LS.

Breast Cancer Res Treat. 2010 Nov;124(1):153-61. doi: 10.1007/s10549-010-1121-7. Epub 2010 Aug 21.

PMID:
20730486
37.

Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients.

Kilburn L, Okcu MF, Wang T, Cao Y, Renfro-Spelman A, Aldape KD, Gilbert MR, Bondy M.

Cancer. 2010 May 1;116(9):2242-9. doi: 10.1002/cncr.25006.

38.

Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates.

Kilburn LB, Bonate PL, Blaney SM, McGuffey L, Nuchtern JG, Dauser R, Thompson P, Gibson BW, Berg SL.

Cancer Chemother Pharmacol. 2009 Jul;64(2):335-40. doi: 10.1007/s00280-008-0875-7. Epub 2008 Nov 29.

PMID:
19043710
39.

Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma.

Barahmani N, Carpentieri S, Li XN, Wang T, Cao Y, Howe L, Kilburn L, Chintagumpala M, Lau C, Okcu MF.

Neuro Oncol. 2009 Jun;11(3):292-300. doi: 10.1215/15228517-2008-089. Epub 2008 Oct 24.

40.

Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate.

Bradley DP, Tessier JJ, Lacey T, Scott M, Jürgensmeier JM, Odedra R, Mills J, Kilburn L, Wedge SR.

Magn Reson Imaging. 2009 Apr;27(3):377-84. doi: 10.1016/j.mri.2008.07.021. Epub 2008 Sep 23.

PMID:
18814988
41.

Combining fulvestrant (Faslodex) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: the SoFEA trial.

Dodwell D, Coombes G, Bliss JM, Kilburn LS, Johnston S; SoFEA Trial Management Group.

Clin Oncol (R Coll Radiol). 2008 Jun;20(5):321-4. doi: 10.1016/j.clon.2008.02.010. Epub 2008 Apr 2. No abstract available.

PMID:
18387790
42.

'Triple negative' breast cancer: a new area for phase III breast cancer clinical trials.

Kilburn LS; TNT Trial Management Group.

Clin Oncol (R Coll Radiol). 2008 Feb;20(1):35-9. Epub 2007 Oct 31. No abstract available.

PMID:
17977700
43.

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study.

Lancet. 2007 Feb 17;369(9561):559-70. Erratum in: Lancet. 2007 Mar 17;369(9565):906.

PMID:
17307102
44.

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC; Intergroup Exemestane Study group.

Lancet Oncol. 2007 Feb;8(2):119-27.

PMID:
17267326
45.

Relative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxifloxacin.

De Azavedo JC, Duncan CL, Kilburn L, Downar J, Kong B, Lad S, Low DE, Bast DJ.

J Chemother. 2006 Aug;18(4):373-8.

PMID:
17024792
46.

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ.

Cancer Res. 2005 May 15;65(10):4389-400.

47.

Impact of the international term breech trial on clinical practice and concerns: a survey of centre collaborators.

Hogle KL, Kilburn L, Hewson S, Gafni A, Wall R, Hannah ME.

J Obstet Gynaecol Can. 2003 Jan;25(1):14-6.

PMID:
12548320
48.

Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae.

Bast DJ, de Azavedo JC, Tam TY, Kilburn L, Duncan C, Mandell LA, Davidson RJ, Low DE.

Antimicrob Agents Chemother. 2001 Sep;45(9):2631-4.

49.

A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae.

Weiss K, Restieri C, Gauthier R, Laverdière M, McGeer A, Davidson RJ, Kilburn L, Bast DJ, de Azavedo J, Low DE.

Clin Infect Dis. 2001 Aug 15;33(4):517-22. Epub 2001 Jul 20.

PMID:
11462189
50.

Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.

Bast DJ, Low DE, Duncan CL, Kilburn L, Mandell LA, Davidson RJ, de Azavedo JC.

Antimicrob Agents Chemother. 2000 Nov;44(11):3049-54.

Supplemental Content

Loading ...
Support Center